Clinical Trial

A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The aim of this trial is to demonstrate similarity in efficacy between ABP 938 8 mg and aflibercept (US) 8 mg by evaluating the change in best corrected visual acuity (BCVA) in participants with neovascular age-related macular degeneration (nAMD)
Protocol Amendment History 3 changes
notable Trial sites expanded: 20 -> 27 locations 2026-07-07
critical Recruitment opened 2026-06-13
notable Trial sites expanded: 0 -> 18 locations 2026-06-13
Trial Details
NCT Number NCT07614776
Lead Sponsor Amgen
Conditions Neovascular Age-related Macular Degeneration, nAMD
Enrollment 304 participants
Start Date 2026-05-27
Primary Completion 2027-07-31 (estimated)
Study Completion 2028-01-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-10